These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 33893689)

  • 1. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
    Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study.
    Zhang W; Yan C; Zhang T; Chen X; Dong J; Zhao J; Han D; Wang J; Zhao G; Cao F; Zhou D; Jiang H; Tang P; Zhao L; Yuan Z; Wang Q; Wang P; Pang Q
    Oncoimmunology; 2021; 10(1):1971418. PubMed ID: 34616588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
    Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
    World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy plus camrelizumab affects peripheral CD8 T-cell differentiation subsets expressing PD-1, TIGIT, and CTLA-4 in esophageal squamous cell carcinoma.
    Guo Z; Zhang K; Wei X; Li Y; Ma X; Li Y; Han D; Du Q; Zhang T; Chen X; Wei H; Yan C; Zhang W; Pang Q; Wang P
    J Leukoc Biol; 2023 Jan; 113(1):11-17. PubMed ID: 36822161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety evaluation of frontline immunotherapy combinations in advanced esophageal squamous cell carcinoma: a network meta-analysis highlighting the value of PD-L1 expression positivity scores.
    Chen W; Cao K; Zhang L; Zhao X; Chen B; Li W; Shang R; Sun L; Jiang Z; Wang J; Xue W
    Front Immunol; 2024; 15():1414753. PubMed ID: 39050848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
    Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
    JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial.
    He M; Wang Z; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Sheng Z; Zeng W; Song L; Xu RH; Luo H
    Med; 2024 Sep; 5(9):1137-1149.e3. PubMed ID: 38870932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer.
    Yan C; Huang H; Zheng Z; Ma X; Zhao G; Zhang T; Chen X; Cao F; Wei H; Dong J; Tang P; Jiang H; Wang M; Wang P; Pang Q; Zhang W
    Front Immunol; 2023; 14():1138054. PubMed ID: 37275884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
    Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
    Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
    Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
    Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
    Zhao W; Ke S; Cai X; Zuo Z; Shi W; Qiu H; Cai G; Gong Y; Wu Y; Ruan S; Chen Y
    Radiother Oncol; 2023 Jul; 184():109679. PubMed ID: 37105302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.
    Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C
    BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.
    Wang X; Zhang B; Chen X; Mo H; Wu D; Lan B; Li Q; Xu B; Huang J
    Thorac Cancer; 2019 Jun; 10(6):1395-1401. PubMed ID: 31017739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study.
    Liu J; Li J; Lin W; Shao D; Depypere L; Zhang Z; Li Z; Cui F; Du Z; Zeng Y; Jiang S; He P; Gu X; Chen H; Zhang H; Lin X; Huang H; Lv W; Cai W; Liang W; Liang H; Jiang W; Wang W; Xu K; Cai W; Wu K; Lerut T; Fu J; He J
    Int J Cancer; 2022 Jul; 151(1):128-137. PubMed ID: 35188268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study.
    Feng T; Li Q; Zhu R; Yu C; Xu L; Ying L; Wang C; Xu W; Wang J; Zhu J; Huang M; Xu C; Jin J; Zhang X; Lu T; Yang Y; Zhu C; Chen Q; Su D
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39209452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
    Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial.
    Yang G; Su X; Huang Y; Luo G; Wang Z; Cai P; Zheng Y; Bei T; Huang M; Bai Y; He H; Xiang J; Cai M; Zhong J; Guo Q; Zhang X
    J Transl Med; 2023 Jun; 21(1):411. PubMed ID: 37355621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
    Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
    Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.